Patrice Verpillat
Overview
Explore the profile of Patrice Verpillat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
957
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mahmoudpour S, Knott C, Nobes J, Kearney M, Boutmy E, Verpillat P, et al.
Br J Dermatol
. 2025 Mar;
PMID: 40036636
No abstract available.
2.
Arlett P, Umuhire D, Verpillat P, Foggi P, Wandel Liminga U, Sepodes B, et al.
Clin Pharmacol Ther
. 2025 Feb;
PMID: 39949283
No abstract available.
3.
Jamal-Allial A, Sponholtz T, Vojjala S, Paullin M, Papazian A, Eshete B, et al.
Pragmat Obs Res
. 2025 Feb;
16:19-25.
PMID: 39936035
Background: The National Death Index (NDI) is the gold standard for mortality data in the United States (US) but has a time lag and can be operationally intensive. This validation...
4.
Beck A, Kampman M, Huynh C, Simon C, Plueschke K, Cohet C, et al.
Clin Pharmacol Ther
. 2024 Oct;
117(2):368-373.
PMID: 39434493
The International Coalition of Medicines Regulatory Authorities (ICMRA), comprising 38 global medicines regulatory authorities, collaborates on shared challenges, notably during the COVID-19 pandemic. This article focuses on the ICMRA COVID-19...
5.
Sponholtz T, Jamal-Allial A, Vojjala S, Papazian A, Eshete B, Paullin M, et al.
Pharmacoepidemiol Drug Saf
. 2024 Aug;
33(8):e5870.
PMID: 39135502
Purpose: We investigated time trends in validation performance characteristics for six sources of death data available within the Healthcare Integrated Research Database (HIRD) over 8 years. Methods: We conducted a...
6.
Mahmoudpour S, Knott C, Kearney M, Russo L, Verpillat P
Urol Oncol
. 2024 Jul;
42(12):451.e11-451.e18.
PMID: 39069443
Introduction: Systemic anticancer therapy for locally advanced or metastatic urothelial carcinoma (la/mUC) is associated with efficacy benefits, including longer overall survival (OS), but many patients remain untreated. This observational, real-world,...
7.
Prilla S, Groeneveld S, Pacurariu A, Restrepo-Mendez M, Verpillat P, Torre C, et al.
Clin Pharmacol Ther
. 2024 Jul;
116(5):1188-1197.
PMID: 38962830
Studies using real-world data (RWD) can complement evidence from clinical trials and fill evidence gaps during different stages of a medicine's lifecycle. This review presents the experience resulting from the...
8.
Almeida D, Umuhire D, Gonzalez-Quevedo R, Antonio A, Burgos J, Verpillat P, et al.
Front Med (Lausanne)
. 2024 Jun;
11:1408636.
PMID: 38846141
Patient experience data (PED), provided by patients/their carers without interpretation by clinicians, directly capture what matters more to patients on their medical condition, treatment and impact of healthcare. PED can...
9.
Bielfeld A, Schwarze J, Verpillat P, Lispi M, Fischer R, Hayward B, et al.
Reprod Biomed Online
. 2024 Apr;
48(6):103725.
PMID: 38593745
Research Question: According to real-world data, is recombinant human FSH (r-hFSH) combined with recombinant human LH (r-hLH) or r-hFSH alone more effective for women of advanced maternal age (AMA) in...
10.
Acha V, Barefoot B, Juarez Garcia A, Lehner V, Monno R, Sandler S, et al.
Ther Innov Regul Sci
. 2023 Jul;
57(6):1199-1208.
PMID: 37460826
This reflection paper presents a consolidated view of EFPIA on the need for principles for good practice in the generation and use of non-interventional studies (NIS), including overarching principles such...